VISCHER AG has advised Oculis. Oculis Holding AG has entered into an asset purchase agreement with Accure Therapeutics, S.L., to acquire all worldwide development and commercial...
Oculis Acquires Global Rights to Privosegtor and ACT-02 from Accure Therapeutics
Oculis Holding AG Secures USD 110 Million Through Share Offerings
VISCHER AG has advised Oculis Holding AG. Oculis Holding AG, a global biopharmaceutical company listed on Nasdaq and XICE, has announced the successful pricing of offerings...
Aktiia Raises USD 42 Million in Series B to Support Global Expansion
VISCHER has advised Earlybird Health, Wellington Partners, Kfund, and naturalX Health Ventures. Aktiia, a company specializing in blood pressure intelligence technology, has successfully raised USD 42...
Memo Therapeutics AG’s CHF20 Million Additional Series C Financing Round
VISCHER advised Ysios Capital and Kurma Partners. Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised...
Artiria Medical SA’s CHF6 Million Series A2 Financing Round
VISCHER acted for Artiria Medical SA on the deal. Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation neuro-interventional products for stroke and aneurysms, closed...
Memo Therapeutics AG’s CHF25 Million Series C Financing Round
VISCHER advised Memo Therapeutics on the financing. Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round...
Prima Materia’s €10 Million Investment From Epiterna
VISCHER advises Epiterna with Prima Materia investment. Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro...
Anokion’s $35 Million Equity Funding from Pfizer
Vischer advised Anokion in this transaction, while Walder Wyss advised Pfizer. Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune...
European Biotech Acquisition’s $200 Million Combination With Oculis
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
Genfit’s Acquisition of Versantis
VISCHER AG advised Versantis with Mark Fitzpatrick as CEO, Vincent Forster as CSO and Meriam Kabbaj as COO. Goodwin advised the sellers. Linklaters and Niederer Kraft...
Novaremed’s Option and License Agreement With NeuroFront
VISCHER advised Novaremed AG on the deal. Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience...
Engimmune Therapeutics’ CHF 15.5 Million Seed Financing Round
Walder Wyss advised Engimmune Therapeutics on the deal. Vischer advised the investors Pureos Bio-ventures and Novo Holdings. Engimmune Therapeutics completed a CHF 15.5m seed financing round co-led...